MY200629A - Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors - Google Patents

Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors

Info

Publication number
MY200629A
MY200629A MYPI2020000251A MYPI2020000251A MY200629A MY 200629 A MY200629 A MY 200629A MY PI2020000251 A MYPI2020000251 A MY PI2020000251A MY PI2020000251 A MYPI2020000251 A MY PI2020000251A MY 200629 A MY200629 A MY 200629A
Authority
MY
Malaysia
Prior art keywords
compounds
pyrazolo
kinase inhibitors
jak kinase
bicyclic compounds
Prior art date
Application number
MYPI2020000251A
Other languages
English (en)
Inventor
Erik Fenster
Tom M Lam
Mandy Loo
Robert Murray Mckinnell
Anthony Francesco Palermo
Diana Jin Wang
Breena Fraga
Jerry Nzerem
Marta Dabros
Venkat R Thalladi
Miroslav Rapta
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MY200629A publication Critical patent/MY200629A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI2020000251A 2017-08-01 2018-07-31 Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors MY200629A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762539642P 2017-08-01 2017-08-01
PCT/US2018/044508 WO2019027960A1 (en) 2017-08-01 2018-07-31 BICYCLIC PYRAZOLO AND TRIAZOLO COMPOUNDS AS JAK KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
MY200629A true MY200629A (en) 2024-01-06

Family

ID=63209687

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020000251A MY200629A (en) 2017-08-01 2018-07-31 Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors

Country Status (23)

Country Link
US (4) US10392368B2 (https=)
EP (1) EP3652169A1 (https=)
JP (2) JP7098716B2 (https=)
KR (1) KR20200036004A (https=)
CN (1) CN111032646B (https=)
AR (1) AR112348A1 (https=)
AU (1) AU2018312349A1 (https=)
BR (1) BR112020002265A2 (https=)
CA (1) CA3069990A1 (https=)
CL (1) CL2020000283A1 (https=)
CO (1) CO2020001469A2 (https=)
EA (1) EA038912B1 (https=)
IL (1) IL272031A (https=)
MA (1) MA49570A (https=)
MX (1) MX2020001170A (https=)
MY (1) MY200629A (https=)
PE (1) PE20201028A1 (https=)
PH (1) PH12020500201A1 (https=)
SG (1) SG11202000602YA (https=)
TW (1) TW201920150A (https=)
UA (1) UA125318C2 (https=)
WO (1) WO2019027960A1 (https=)
ZA (1) ZA202000561B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018312349A1 (en) 2017-08-01 2020-02-06 Theravance Biopharma R&D Ip, Llc Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
CN113498352A (zh) 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
EP3999055A1 (en) * 2019-07-15 2022-05-25 Novartis AG Methods for treating meibomian gland dysfunction with liver x receptor agonists
CA3179566A1 (en) * 2020-04-08 2021-10-14 Pfizer Inc. Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof
CN115867272A (zh) * 2020-05-14 2023-03-28 施万生物制药研发Ip有限责任公司 肠道选择性jak3抑制剂的给药
CN114075220A (zh) * 2020-08-13 2022-02-22 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
US20230339977A1 (en) * 2020-08-13 2023-10-26 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compound, and composition and application thereof
WO2022053000A1 (zh) * 2020-09-10 2022-03-17 四川海思科制药有限公司 一种碳环酰胺衍生物及其在医药上的应用
EP4271380A4 (en) * 2020-12-29 2025-01-22 Abbvie Inc. UPADACITINIB EXTENDED RELEASE FORMULATIONS
WO2022199599A1 (zh) * 2021-03-23 2022-09-29 凯复(苏州)生物医药有限公司 丙烯酰基取代的化合物、包含其的药物组合物及其用途
CN117377667A (zh) * 2021-03-29 2024-01-09 百时美施贵宝公司 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型
CN113061137B (zh) * 2021-04-02 2022-08-02 广西医科大学 含氮杂环衍生物或其药学上可接受的盐和用途
UA129643C2 (uk) * 2021-05-03 2025-06-18 Інсайт Корпорейшн Інгібітори шляху jak1 для лікування вузлуватого свербця
US20250051360A1 (en) * 2021-12-23 2025-02-13 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compound, and composition and use thereof
WO2023165562A1 (zh) * 2022-03-02 2023-09-07 南京明德新药研发有限公司 含氮杂环类化合物及其应用
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213163D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2025201397A1 (en) * 2024-03-27 2025-10-02 Insilico Medicine Ip Limited Tead inhibitors and methods of uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1293073C (zh) 2001-04-20 2007-01-03 惠氏公司 作为5－羟色胺－6配体的杂环基烷氧基－、－烷硫基－和－烷基氨基吲哚衍生物
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
DK1638941T3 (da) 2003-05-22 2010-10-11 Abbott Lab Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer
EP1647549A1 (en) 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
EP1959926A1 (en) 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
JP2009532375A (ja) 2006-03-30 2009-09-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
KR100834758B1 (ko) 2006-07-05 2008-06-05 삼성전자주식회사 컴퓨터 시스템 보안 장치 및 방법
JP2009007342A (ja) 2007-06-01 2009-01-15 Mitsubishi Tanabe Pharma Corp 医薬組成物
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
WO2009147189A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
WO2009147188A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Benzpyrazol derivatives as inhibitors of pi3 kinases
ES2383246T3 (es) 2008-06-05 2012-06-19 Glaxo Group Limited 4-amino-indazoles
US8653069B2 (en) 2008-07-28 2014-02-18 Jiangsu Hengyi Pharmaceutical Co., Ltd. Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia
TW201111385A (en) 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
FR2951172B1 (fr) 2009-10-13 2014-09-26 Pf Medicament Derives pyrazolopyridines en tant qu'agent anticancereux
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2012061537A2 (en) 2010-11-02 2012-05-10 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN102993201A (zh) * 2011-09-14 2013-03-27 赛诺菲 作为激酶抑制剂的6-(4-羟基-苯基)-3-苯乙烯基-1H-吡唑并[3，4-b]吡啶-4-羧酸酰胺衍生物
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US20130102601A1 (en) 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
EP2771340B1 (en) 2011-10-25 2016-04-13 Sanofi 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2788000B1 (en) * 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
WO2013167403A1 (en) 2012-05-09 2013-11-14 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
TWI629275B (zh) * 2013-03-13 2018-07-11 賽諾菲公司 Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途
JP2016113366A (ja) * 2013-03-29 2016-06-23 大鵬薬品工業株式会社 アセトアミド基を有する１，２，４−トリアジン−６−カルボキサミド誘導体
SI3077395T1 (en) 2013-12-05 2018-03-30 Pfizer Inc. Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides
EP3097091A1 (en) 2014-01-24 2016-11-30 AbbVie Inc. 6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use
WO2015131080A1 (en) * 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
KR20170002623A (ko) 2014-05-14 2017-01-06 화이자 인코포레이티드 피라졸로피리딘 및 피라졸로피리미딘
US10519160B2 (en) 2014-07-18 2019-12-31 The General Hospital Corporation Imaging agents for neural flux
WO2016071293A2 (en) 2014-11-03 2016-05-12 Iomet Pharma Ltd Pharmaceutical compound
CN105837574B (zh) 2015-02-02 2018-03-02 四川大学 N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途
EP3288943B1 (en) * 2015-05-01 2022-09-28 Pfizer Inc. Pyrrolo[2,3-b]pyrazinyl acrylamides and epoxides thereof as inhibitors of janus kinase
CA2985185A1 (en) 2015-05-07 2016-11-10 The Trustees Of Columbia University In The City Of New York Methods and compositions for promoting hair growth
WO2017077283A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
US10973913B2 (en) 2016-02-16 2021-04-13 Washington University JAK inhibitors and uses thereof
MX388591B (es) 2016-06-30 2025-03-20 Daewoong Pharmaceutical Co Ltd Derivados de pirazolopirimidina como inhibidor de cinasa.
EP3509572A4 (en) 2016-09-08 2020-05-13 Synergistic Therapeutics, LLC TOPICAL FORMULATION FOR HAIR GROWTH
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
US20180117148A1 (en) 2016-10-28 2018-05-03 Andrew J. Holman Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders
KR102032418B1 (ko) * 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
AU2018312349A1 (en) 2017-08-01 2020-02-06 Theravance Biopharma R&D Ip, Llc Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
KR102821964B1 (ko) 2017-11-03 2025-06-19 어클라리스 쎄라퓨틱스, 인코포레이티드 치환된 피롤로피리미딘 jak 억제제 및 이의 제조 및 사용 방법
RU2758370C1 (ru) 2017-12-28 2021-10-28 Даевунг Фармасьютикал Ко., Лтд. Производные оксифторпиперидина в качестве ингибитора киназы
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
CN113498352A (zh) * 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
CN115867272A (zh) * 2020-05-14 2023-03-28 施万生物制药研发Ip有限责任公司 肠道选择性jak3抑制剂的给药

Also Published As

Publication number Publication date
CA3069990A1 (en) 2019-02-07
IL272031A (en) 2020-03-31
WO2019027960A1 (en) 2019-02-07
CN111032646B (zh) 2023-01-03
US20190040043A1 (en) 2019-02-07
CN111032646A (zh) 2020-04-17
AU2018312349A1 (en) 2020-02-06
BR112020002265A2 (pt) 2020-07-28
SG11202000602YA (en) 2020-02-27
EA202090413A1 (ru) 2020-06-24
CO2020001469A2 (es) 2020-05-29
AR112348A1 (es) 2019-10-16
MA49570A (fr) 2020-05-20
US10968205B2 (en) 2021-04-06
CL2020000283A1 (es) 2020-06-12
TW201920150A (zh) 2019-06-01
US20200216423A1 (en) 2020-07-09
PH12020500201A1 (en) 2020-10-12
US20190315724A1 (en) 2019-10-17
US20220119369A1 (en) 2022-04-21
MX2020001170A (es) 2020-03-12
ZA202000561B (en) 2022-04-28
EP3652169A1 (en) 2020-05-20
JP7098716B2 (ja) 2022-07-11
US10538513B2 (en) 2020-01-21
JP2021098751A (ja) 2021-07-01
JP2020529987A (ja) 2020-10-15
US10392368B2 (en) 2019-08-27
UA125318C2 (uk) 2022-02-16
KR20200036004A (ko) 2020-04-06
PE20201028A1 (es) 2020-10-05
EA038912B1 (ru) 2021-11-09

Similar Documents

Publication Publication Date Title
PH12020500201A1 (en) Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
PH12017502050A1 (en) Naphthyridine compounds as jak kinase inhibitors
PH12019501985A1 (en) Fused imidazo-piperidine jak inhibitors
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
PH12020500528A1 (en) Pyrimidine compound as jak kinase inhibitor
EA201892436A1 (ru) Пиримидиновые соединения в качестве ингибиторов jak киназы
PH12018500944B1 (en) [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND
TW201613925A (en) Imidazopyrazines as LSD1 inhibitors
ZA201802496B (en) Jak kinase inhibitor compounds for treatment of respiratory disease
MX2020003458A (es) Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[ 5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3- carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo.
MX370390B (es) Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados.
HK1211942A1 (en) Pyrazolopyrimidine compounds as kinase inhibitors
MX390505B (es) Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2
MX386174B (es) Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2
NZ740119A (en) Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide
EA202192822A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
MY192305A (en) Bipyrazole derivatives as jak inhibitors